Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)

Hypercholesterolemia Clinical Trial

Official title:

A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00413972
• Other study ID #: P04420
• Secondary ID: SCH 465981
• Status: Completed
• Phase: Phase 3
• Start date: April 2006
• Est. completion date: November 2006

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study of Vytorin 10/10 (ezetimibe 10 mg with simvastatin 10 mg), Vytorin 10/20 (ezetimibe 10 mg with simvastatin 20 mg), and Vytorin 10/40 (ezetimibe 10 mg with simvastatin 40 mg) compared to placebo administered daily for 8 consecutive weeks in subjects with primary hypercholesterolemia (LDL-C >3.64 mmol/L [140 mg/dL]). The efficacy of daily Vytorin versus placebo in reducing the concentration of LDL-C will be evaluated, and the efficacy of daily Vytorin versus placebo with respect to change in the concentrations of total cholesterol, triglycerides, and HDL-C will be compared. The safety of Vytorin versus placebo will also be assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 392
• Est. completion date: November 2006
• Est. primary completion date: November 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects must be >=18 years and <=75 years of age, male or female.

• Primary hypercholesterolemic subject with a plasma LDL cholesterol concentration >3.64 mmol/L (140 mg/dL) to <=6.3 mmol/L (250 mg/dL) using the Friedewald calculation; total cholesterol (TC) >5.2 mmol/L (200 mg/dL) to <12.7 mmol/L (500 mg/dL) and triglyceride concentrations of <=3.99 mmol/L (350 mg/dL) should be met at the same time. At the time of recruitment (Visit 1), these values may be lower if the subject is on lipid-lowering therapy. (ie, prior to the start of lipid lowering drug washout) or may be higher at the start of dietary therapy.

• Liver transaminases (ALT, AST) <=50% above the upper limit of normal, with no active liver disease and CK <=50% above the upper limit of normal.

• Clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) must be within normal limits, or clinically acceptable to the investigator/sponsor.

• Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control.

• Subjects must be free of any clinically significant diseases other than hyperlipidemia that would interfere with study evaluations.

• Subjects must understand and be able to adhere to the dosing and visit schedules.

• Subject must agree to remain on a cholesterol-lowering diet for the duration of the study (according to China Adult Treatment Panel of High Blood Cholesterol).

Exclusion Criteria:

• Subjects whose body mass index (BMI=weight [kg]/height2 [m]) is >=30 kg/m2 at Visit 3 (Baseline Visit).

• Subjects who have known hypersensitivity to HMG CoA reductase inhibitors.

• Subjects who consume >14 alcoholic drinks per week. (A drink is: a can of beer, glass of wine, or single measure of spirits).

• Any condition or situation, which in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study.

• Women who are pregnant or nursing.

• Subjects who have not observed the designated washout periods for any of the prohibited medications.

• Congestive heart failure defined by NYHA as Class III or IV.

• Uncontrolled cardiac arrhythmia.

• Myocardial infarction, coronary bypass surgery, or angioplasty within 6 months of study entry.

• Unstable or severe peripheral artery disease within 3 months of study entry.

• Unstable angina pectoris within 6 months of study entry.

• Uncontrolled hypertension (treated or untreated) with systolic blood pressure >160 mm Hg or diastolic >100 mm Hg at study entry.

• Uncontrolled (as determined by fasting glucose >180 mg/mL or HbA1c >9%) or newly diagnosed (within 1 month of study entry) diabetes mellitus.

• Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, ie, secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone [TSH] above upper limit of normal). Subjects with a history of hypothyroidism who are on a stable therapy of thyroid hormone replacement for at least 6 weeks are eligible for enrollment if TSH levels are within normal limits before enrollment.

• Known impaired renal function (plasma creatinine >2.0 mg/dL), or nephrotic syndrome at study entry.

• Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.

• Known HIV positive.

• Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).

• History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.

• Female subject receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives.

Related Conditions & MeSH terms

• Hypercholesterolemia

Intervention

Drug:
• ezetimibe with simvastatin
Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
• Ezetimibe with Simvastatin
Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
• Ezetimibe with Simvastatin
Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
• Placebo
Placebo once daily for a total of eight weeks

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Organon and Co	Merck Sharp & Dohme Corp., Schering-Plough

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment		Baseline, 8 weeks